Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies

Abstract Aims/Introduction We evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum potassium elevation in Japanese patients with diabetic kidney disease. Materials and Methods We carried out a prespecified subanalys...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Kenichi Shikata, Sadayoshi Ito, Naoki Kashihara, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori, Kotaro Sugimoto
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Wiley 2022-07-01
Seri Bilgileri:Journal of Diabetes Investigation
Konular:
Esaxerenone
Potassium
Sodium–glucose transporter 2 inhibitor
Online Erişim:https://doi.org/10.1111/jdi.13778

Internet

https://doi.org/10.1111/jdi.13778

Benzer Materyaller